embecta Corp., the Morris County-headquartered leader in diabetes technology, announced a definitive agreement Thursday to acquire Owen Mumford Holdings Limited, a UK-based innovator in drug-delivery devices. The deal, valued at up to approx. $190 million, marks a pivotal shift for the Parsippany firm as it transforms into a broad-based medical supplies giant.
The acquisition is structured with an upfront cash payment of approximately $133 million, with an additional $66.5 million available in performance-based milestones tied to the success of Owen Mumford’s next-generation Aidaptus® auto-injector platform.
For embecta, which spun off from Becton Dickinson (BD) with a century-long legacy in insulin delivery, the move is a strategic play to capture the booming market for self-injection therapies. While embecta is a household name in diabetes, Owen Mumford brings expertise in devices for obesity, autoimmune diseases, and anaphylaxis.
“This acquisition is expected to sustainably improve embecta’s revenue growth trajectory,” said Devdatt (Dev) Kurdikar, Chairman, President, and CEO of embecta. “[It] will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients across multiple markets.”
A primary driver of the acquisition is the Aidaptus® auto-injector. This platform is designed to handle a variety of drug volumes and viscosities with a single final assembly process, a “one-size-fits-most” approach that reduces supply chain complexity for pharmaceutical partners.
By integrating Owen Mumford’s design and molding capabilities with embecta’s massive manufacturing scale, the combined company expects to create significant operational efficiencies.
Though Owen Mumford is an established innovator—having pioneered the first plastic autoinjector—roughly 80% of its 2025 revenue came from the UK and the U.S. embecta plans to use its existing commercial infrastructure, which spans more than 100 countries, to scale these products globally.
The board of directors for embecta has unanimously approved the transaction, which is expected to close in the third fiscal quarter of 2026.
- Revenue Growth: embecta anticipates the acquisition will contribute to top-line growth starting in fiscal year 2027.
- Profitability: The deal is expected to be accretive to adjusted operating income after 2027, with a high-single-digit return on invested capital projected by year four.
- Financing: The company intends to finance the upfront cost through its revolving credit facility while remaining committed to long-term debt reduction.
The Parsippany-based leadership team is expected to discuss the acquisition in further detail during their fiscal second-quarter earnings call on May 5.
